Minocycline Therapeutic Potential in Psychiatry
Olivia M Dean, Joao Data-Franco, Francesco Giorlando, Michael Berk
CNS Drugs | ADIS INT LTD | Published : 2012
No sources of funding were used to prepare this review. MB has received grant/research support from the NIH, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma and Servier; has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth; and served as a consultant to Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck and Servier. FG has received grant/research support from the ASBD, AstraZeneca, Pfizer and the RANZCP. OD has received grant/research support from Simons Autism Foundation, Stanley Medical Research Institute, NHMRC and an ASBD/Servier grant. JF has no potential conflicts of interest.